文献速递血管炎

血管炎症中的IL-6轴:IL-6受体阻断对巨细胞动脉炎患者血管病变的影响

The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritis.
PubMed 文献 · Ann Rheum Dis · 2025-03-11

本研究采用假设驱动的候选分子转录组学方法,对巨细胞动脉炎(GCA)患者颞动脉和主动脉组织进行离体培养,发现IL-6受体蛋白在GCA中表达增强;托珠单抗可降低STAT3磷酸化及STAT3依赖分子表达,减少外周血单核细胞(PBMC)黏附和趋化,但部分标本中托珠单抗增加STAT1磷酸化及STAT1依赖趋化因子表达。

要点

  • IL-6受体蛋白在GCA动脉中密集表达,高于对照动脉。
  • 托珠单抗降低培养的GCA受累动脉和PBMC中STAT3磷酸化及STAT3依赖分子表达。
  • 部分标本中托珠单抗增加STAT1磷酸化及CXCL9、CXCL10表达,可能为逃逸机制。

核心结论

  • 托珠单抗通过减少(而非消除)PBMC募集的关键分子,对血管病变产生显著影响。
  • 约半数患者可能在病变中激活替代炎症通路,作为对托珠单抗的潜在逃逸机制,值得进一步研究。

研究设计与样本

  • 研究采用假设驱动的候选分子转录组学方法,使用离体颞动脉和主动脉组织培养、定量实时聚合酶链反应、免疫荧光、蛋白质印迹、免疫分析、黏附和趋化试验。

主要发现

  • IL-6受体蛋白在GCA中密集表达,高于对照动脉。
  • 托珠单抗降低培养的GCA受累动脉和患者PBMC中STAT3表达/磷酸化,并减少STAT3依赖分子(包括细胞因子信号传导抑制因子3、CCL-2和ICAM-1)表达;主动脉组织中观察到类似趋势。
  • 托珠单抗降低PBMC对血管平滑肌细胞和人脐静脉内皮细胞的黏附性,以及对托珠单抗处理的GCA动脉上清的趋化性。
  • 部分标本中,托珠单抗增加STAT1磷酸化及STAT1依赖趋化因子(包括CXCL9和CXCL10)表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Blocking interleukin (IL)-6-receptor with tocilizumab has been a major advance in the treatment of giant-cell arteritis (GCA), supporting a crucial role of IL-6 receptor signalling. However, nearly half of the patients are not able to maintain glucocorticoid- free remission with tocilizumab. The impact of tocilizumab on vascular lesions of GCA is largely unknown since conflicting results have been obtained by imaging. The expression and functional role of IL-6-receptor in GCA immunopathology has not been previously investigated. This study aimed to investigate expression of IL-6 receptor in GCA and control arteries and to assess the impact of tocilizumab on ex vivo-cultured temporal arteries and aortic tissue from patients with GCA. METHODS: This study used a hypothesis-driven, candidate molecule transcriptomic approach using ex vivo temporal artery and aortic tissue culture, quantitative real-time polymerase chain reaction, immunofluorescence, Western Blot, immunoassay, adhesion, and chemotaxis assays. RESULTS: IL-6 receptor protein expressed intensively in GCA compared with that in control arteries. Tocilizumab decreased expression/phosphorylation of STAT3 and reduced expression of STAT3-dependent molecules including suppressor of cytokine signalling 3, CCL-2, and ICAM-1 in cultured GCA-involved arteries and patients' peripheral blood mononuclear cells (PBMCs). A similar trend was observed in aortic tissue. Consistently, tocilizumab reduced PBMC adhesiveness to vascular smooth muscle cells and human umbilical vein endothelial cells and chemotaxis towards supernatants of tocilizumab-treated GCA arteries. In some specimens, tocilizumab increased STAT1 phosphorylation and expression of STAT1-dependent chemokines including CXCL9 and CXCL10. CONCLUSIONS: Tocilizumab has a significant impact on vascular lesions by reducing, but not abrogating, key molecules involved in PBMC recruitment. About half of the patients may activate alternative inflammatory pathways in their lesions as a potential escape mechanism to tocilizumab that deserves further investigation.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Corbera-Bellalta M, Kamberovic F, Alba-Rovira R, et al. The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritis. Ann Rheum Dis. 2025. PMID: 40074597. doi:10.1016/j.ard.2025.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。